Rectal fistulae resulting from treatment with sorafenib and bevacizumab

Gastrointest Endosc. 2009 Dec;70(6):1246-7. doi: 10.1016/j.gie.2009.06.027. Epub 2009 Aug 15.

Authors

Erik C von Rosenvinge¹, Lakshmi D Gopal, Theo Heller, Elise C Kohn, Michael D Yao

Affiliation

¹ National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA.

PMID: 19683714
DOI: 10.1016/j.gie.2009.06.027

No abstract available

MeSH terms

Angiogenesis Inhibitors / adverse effects*
Antibodies, Monoclonal / adverse effects*
Antibodies, Monoclonal, Humanized
Antineoplastic Agents / adverse effects*
Benzenesulfonates / adverse effects*
Bevacizumab
Female
Humans
Middle Aged
Niacinamide / analogs & derivatives
Phenylurea Compounds
Pyridines / adverse effects*
Rectal Fistula / chemically induced*
Sorafenib

Substances

Angiogenesis Inhibitors
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Benzenesulfonates
Phenylurea Compounds
Pyridines
Niacinamide
Bevacizumab
Sorafenib